ATRA - Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03 revenue of $4.25M misses by $10.01M
2024-03-28 08:43:25 ET
More on Atara Biotherapeutics
- Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway
- FDA clears Atara to begin Phase 1 study for lupus nephritis drug
- Baupost Group steps away from Atara, Veritiv; bulks up on Clarivate, Jazz Pharma
- Seeking Alpha’s Quant Rating on Atara Biotherapeutics
- Historical earnings data for Atara Biotherapeutics